Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YK-11 is a synthetic, steroidal selective androgen receptor modulator (SARM) known for its potent anabolic effects on muscle cells and bone. It functions as a partial agonist of the androgen receptor and also acts as a myostatin inhibitor by increasing the expression of follistatin, a protein that suppresses muscle growth. YK-11 is classified as an experimental compound and has not been approved for medical use in humans. Despite this, it is widely misused in sports as a performance-enhancing drug and is found in dietary supplements. Preclinical studies have investigated its potential in conditions such as muscle wasting, osteoporosis, obesity, and sepsis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on YK-11.